Rezdiffra (resmetirom) is a prescription drug used to treat certain types of nonalcoholic steatohepatitis (NASH). Rezdiffra can cause side effects that range from mild to serious, such as diarrhea and ...

Rezdiffra (resmetirom) is a brand-name drug prescribed for a type of liver disease called metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) ...

Rezdiffra (resmetirom) has potential interactions with other medications. These interactions could affect how well the drug works or cause harmful effects. Rezdiffra is used in adults to treat ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...

Rezdiffra has interactions with certain drugs, such as clopidogrel, atorvastatin, and gemfibrozil. Talk with your doctor to avoid potentially harmful effects from Rezdiffra interactions. Rezdiffra is ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

--Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis, today announced results from new analyses of the Phase 3 ...

The last time I spoke about Madrigal Pharmaceuticals (MDGL), it was with respect to a Seeking Alpha article entitled "Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term." ...

Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark Office issued a Notice of Allowance for a new U.S. patent related to the ...